Previous 10 |
Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire SAN DIEGO , March 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, ...
Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors Cheryl A. Madsen, RAC appointed as Senior Vice President, Regulator...
Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference PR Newswire SAN DIEGO , March 3, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today...
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc. Company Name:
VIRX Stock Symbol:
NASDAQ Market:
Viracta Therapeutics Inc. Website:
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Mi...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financia...